Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

Breast Cancer Research

Richard M Elledge²  Gary M Clark²  Valerie J Bardou¹  Grazia Arpino² 

[1] Paoli Calmettes Institute, Marseille, France;Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA

关键词: special type of breast cancer;    invasive lobular carcinoma of the breast;    invasive ductal carcinoma of the breast;    infiltrating lobular carcinoma;    infiltrating ductal carcinoma;    breast carcinoma;    breast cancer;   

 received in 2003-12-02, accepted in 2004-01-28,  发布年份 2004

【 摘 要 】

Introduction

Invasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors.

Methods

The clinical and biological features of 4140 patients with ILC were compared with those of 45,169 patients with IDC (not otherwise specified). The median follow-up period was 87 months.

Results

In comparison with IDC, ILC was significantly more likely to occur in older patients, to be larger in size, to be estrogen and progesterone receptor positive, to have lower S-phase fraction, to be diploid, and to be HER-2, p53, and epidermal growth factor receptor negative. It was more common for ILC than for IDC to metastasize to the gastrointestinal tract and ovary. The incidence of contralateral breast cancer was higher for ILC patients than for IDC patients (20.9% versus 11.2%; P < 0.0001). Breast preservation was modestly less frequent in ILC patients than in IDC patients. The 5-year disease-free survival was 85.7% for ILC and 83.5% for IDC (P = 0.13). The 5-year overall survival was 85.6% for ILC and 84.1% for IDC (P = 0.64).

Conclusion

Despite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC. At present, management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology.

【 授权许可】

   
2004 Arpino et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979, 3:467-488.
• [2]Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993, 114:637-641. discussion 641–632
• [3]Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE: Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000, 88:2561-2569.
• [4]Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975, 36:1-85.
• [5]Krecke KN, Gisvold JJ: Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 1993, 161:957-960.
• [6]Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, Ku NN, Baekey PA, Cox CE: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 1995, 222:549-559. discussion 559–561
• [7]Cornford EJ, Wilson AR, Athanassiou E, Galea M, Ellis IO, Elston CW, Blamey RW: Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. Br J Radiol 1995, 68:450-453.
• [8]Helvie MA, Paramagul C, Oberman HA, Adler DD: Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol 1993, 28:202-207.
• [9]Newstead GM, Baute PB, Toth HK: Invasive lobular and ductal carcinoma: mammographic findings and stage at diagnosis. Radiology 1992, 184:623-627.
• [10]Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW, Stewart HJ: Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg 1983, 70:513-516.
• [11]Lesser ML, Rosen PP, Kinne DW: Multicentricity and bilaterality in invasive breast carcinoma. Surgery 1982, 91:234-240.
• [12]du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW: Invasive lobular carcinomas of the breast – the prognosis of histopathological subtypes. Br J Cancer 1989, 60:605-609.
• [13]Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA: A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 1984, 50:23-30.
• [14]Ashikari R, Huvos AG, Urban JA, Robbins GF: Infiltrating lobular carcinoma of the breast. Cancer 1973, 31:110-116.
• [15]Mate TP, Carter D, Fischer DB, Hartman PV, McKhann C, Merino M, Prosnitz LR, Weissberg JB: A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer 1986, 58:1995-2002.
• [16]Davis RP, Nora PF, Kooy RG, Hines JR: Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 1979, 114:485-488.
• [17]Smith DB, Howell A, Wagstaff J: Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987, 23:979-982.
• [18]Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P: Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994, 73:1673-1677.
• [19]Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77:113-120.
• [20]Toikkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997, 76:1234-1240.
• [21]McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 1977, 37:637-639.
• [22]Powell B, Garola RE, Chamness GC, McGuire WL: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 1979, 39:1678-1682.
• [23]Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988, 61:420-427.
• [24]Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, McGuire WL: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993, 71:2157-2162.
• [25]Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989, 320:627-633.
• [26]Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993, 28:9-20.
• [27]Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, Pounds GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992, 84:1279-1282.
• [28]Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17.
• [29]Klijn JG, Berns PM, Bontenbal M, Foekens JA: Growth factors. Clinical implications in breast cancer. Ann N Y Acad Sci 1993, 698:85-101.
• [30]Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206.
• [31]Henson D, Tarone R: A study of lobular carcinoma of the breast based on the Third National Cancer Survey in The United States of America. Tumori 1979, 65:133-142.
• [32]Newman W: Lobular carcinoma of the female breast. Report of 73 cases. Ann Surg 1966, 164:305-314.
• [33]Rosen P: The Pathology of Invasive Breast Carcinoma. 2nd edition. Philadelphia: Lippincott; 1991.
• [34]Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000, 92:550-556.
• [35]MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F, Coindre JM: Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 1997, 10:769-776.
• [36]Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991, 48:28-33.
• [37]Harake MD, Maxwell AJ, Sukumar SA: Primary and metastatic lobular carcinoma of the breast. Clin Radiol 2001, 56:621-630.
• [38]Winston CB, Hadar O, Teitcher JB, Caravelli JF, Sklarin NT, Panicek DM, Liberman L: Metastatic lobular carcinoma of the breast: patterns of spread in the chest, abdomen, and pelvis on CT. AJR Am J Roentgenol 2000, 175:795-800.
• [39]Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM: Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000, 114:190-196.
• [40]Lamovec J, Zidar A: Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 1991, 115:507-510.
• [41]Wheeler JE, Enterline HT: Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu 1976, 11:161-188.
• [42]Fechner RE: Infiltrating lobular carcinoma without lobular carcinoma in situ. Cancer 1972, 29:1539-1545.
• [43]Helin ML, Helle MJ, Helin HJ, Isola JJ: Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med 1989, 113:854-857.
• [44]Poen JC, Tran L, Juillard G, Selch MT, Giuliano A, Silverstein M, Fingerhut A, Lewinsky B, Parker RG: Conservation therapy for invasive lobular carcinoma of the breast. Cancer 1992, 69:2789-2795.
• [45]Soslow RA, Carlson DL, Horenstein MG, Osborne MP: A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat 2000, 61:161-170.
• [46]Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin PM, Bolla M, Spyratos F: S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res 2001, 7:909-917.
• [47]Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M: Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 1993, 423:497-502.
• [48]Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995, 13:821-830.
• [49]Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995, 75:1320-1326.
• [50]Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathology 1982, 6:149-161.
• [51]DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M: Prognosis in infiltrating lobular carcinoma. An analysis of 'classical' and variant tumors. Am J Surg Pathol 1990, 14:12-23.
• [52]Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
• [53]Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975, 36:1-85.
• [54]Horn PL, Thompson WD: Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 1988, 128:309-323.
• [55]Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG: An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol 1995, 8:830-836.